A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

Exclusion Criteria

• •Immunosuppressed patients (history of transplantation, cancer, chemotherapy, splenectomy, or HIV)
• •Application of topical immunomodulatory or immunosuppressive agent in the preceding 6 weeks.
• •Systemic administration of corticosteroid or other systemic treatment (i.e., prednisone) that has immunomodulatory or other immunosuppressive mechanisms of action, in the preceding 3 months or planned usage throughout the study.
• •Clinical evidence of secondary skin infection (i.e., folliculitis).
• •Other scalp conditions (i.e., seborrheic dermatitis or dissecting cellulitis) that might interfere with evaluations during the study.
• •Investigational medications within the past 30 days.
• •Female prospective subject is pregnant, nursing, planning a pregnancy, or less than six months postpartum.
• •Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies.
• •Use of photobiomodulating device, such as those in this study, within the past 4 weeks
• •Initiation or change in dose/application of topical minoxidil within the past 6 weeks.
• •Finasteride or dutasteride within the last 3 months.
• •Spironolactone within the past 3 months.
• •Vitamin supplementation (i.e. selenium, or biotin) in excess of daily recommendation per manufacturer.
• •Lesions in the treated area suspicious for malignancy, or prior skin cancer.
• •Radiation or chemotherapy to the scalp.
• •Use of topical or oral ketoconazole in the past 4 weeks.
• •Hair transplant procedure within the past 6 months or throughout the duration of the study.
• •History of microneedling procedure performed on scalp.
• •Changes in hair style while enrolled in the study.
• •Current weave, or plans to get a weave while enrolled in the study.